1
|
Xiao Z, Wei H, Xu Y, Haider A, Wei J, Yuan S, Rong J, Zhao C, Li G, Zhang W, Chen H, Li Y, Zhang L, Sun J, Zhang S, Luo HB, Yan S, Cai Q, Hou L, Che C, Liang SH, Wang L. Discovery of a highly specific 18F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofluorination. Acta Pharm Sin B 2022; 12:1963-1975. [PMID: 35847497 PMCID: PMC9279629 DOI: 10.1016/j.apsb.2021.11.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Revised: 09/30/2021] [Accepted: 10/20/2021] [Indexed: 12/14/2022] Open
Abstract
As a member of cyclic nucleotide phosphodiesterase (PDE) enzyme family, PDE10A is in charge of the degradation of cyclic adenosine (cAMP) and guanosine monophosphates (cGMP). While PDE10A is primarily expressed in the medium spiny neurons of the striatum, it has been implicated in a variety of neurological disorders. Indeed, inhibition of PDE10A has proven to be of potential use for the treatment of central nervous system (CNS) pathologies caused by dysfunction of the basal ganglia–of which the striatum constitutes the largest component. A PDE10A-targeted positron emission tomography (PET) radioligand would enable a better assessment of the pathophysiologic role of PDE10A, as well as confirm the relationship between target occupancy and administrated dose of a given drug candidate, thus accelerating the development of effective PDE10A inhibitors. In this study, we designed and synthesized a novel 18F-aryl PDE10A PET radioligand, codenamed [18F]P10A-1910 ([18F]9), in high radiochemical yield and molar activity via spirocyclic iodonium ylide-mediated radiofluorination. [18F]9 possessed good in vitro binding affinity (IC50 = 2.1 nmol/L) and selectivity towards PDE10A. Further, [18F]9 exhibited reasonable lipophilicity (logD = 3.50) and brain permeability (Papp > 10 × 10−6 cm/s in MDCK-MDR1 cells). PET imaging studies of [18F]9 revealed high striatal uptake and excellent in vivo specificity with reversible tracer kinetics. Preclinical studies in rodents revealed an improved plasma and brain stability of [18F]9 when compared to the current reference standard for PDE10A-targeted PET, [18F]MNI659. Further, dose–response experiments with a series of escalating doses of PDE10A inhibitor 1 in rhesus monkey brains confirmed the utility of [18F]9 for evaluating target occupancy in vivo in higher species. In conclusion, our results indicated that [18F]9 is a promising PDE10A PET radioligand for clinical translation.
Collapse
Affiliation(s)
- Zhiwei Xiao
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114, USA
| | - Huiyi Wei
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
| | - Yi Xu
- Department of Cardiology, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
| | - Ahmed Haider
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114, USA
| | - Junjie Wei
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
| | - Shiyu Yuan
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
| | - Jian Rong
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114, USA
| | - Chunyu Zhao
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114, USA
| | - Guocong Li
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
| | - Weibin Zhang
- State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| | - Huangcan Chen
- State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| | - Yuefeng Li
- Guangdong Landau Biotechnology Co. Ltd., Guangzhou 510555, China
| | - Lingling Zhang
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
| | - Jiyun Sun
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114, USA
| | - Shaojuan Zhang
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
| | - Hai-Bin Luo
- Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China
| | - Sen Yan
- Guangdong-Hongkong-Macau Institute of CNS Regeneration, Ministry of Education CNS Regeneration Collaborative Joint Laboratory, Jinan University, Guangzhou 510632, China
| | - Qijun Cai
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
| | - Lu Hou
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
| | - Chao Che
- State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518055, China
- Corresponding authors. Tel./fax: +86 755 26032530 (Chao Che), +1 617 7266165 (Steven H. Liang), +86 20 38688692 (Lu Wang).
| | - Steven H. Liang
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital & Department of Radiology, Harvard Medical School, Boston, MA 02114, USA
- Corresponding authors. Tel./fax: +86 755 26032530 (Chao Che), +1 617 7266165 (Steven H. Liang), +86 20 38688692 (Lu Wang).
| | - Lu Wang
- Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China
- Corresponding authors. Tel./fax: +86 755 26032530 (Chao Che), +1 617 7266165 (Steven H. Liang), +86 20 38688692 (Lu Wang).
| |
Collapse
|
2
|
Pyrazoles as Key Scaffolds for the Development of Fluorine-18-Labeled Radiotracers for Positron Emission Tomography (PET). Molecules 2020; 25:molecules25071722. [PMID: 32283680 PMCID: PMC7181023 DOI: 10.3390/molecules25071722] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2020] [Revised: 04/02/2020] [Accepted: 04/08/2020] [Indexed: 02/07/2023] Open
Abstract
The need for increasingly personalized medicine solutions (precision medicine) and quality medical treatments, has led to a growing demand and research for image-guided therapeutic solutions. Positron emission tomography (PET) is a powerful imaging technique that can be established using complementary imaging systems and selective imaging agents—chemical probes or radiotracers—which are drugs labeled with a radionuclide, also called radiopharmaceuticals. PET has two complementary purposes: selective imaging for diagnosis and monitoring of disease progression and response to treatment. The development of selective imaging agents is a growing research area, with a high number of diverse drugs, labeled with different radionuclides, being reported nowadays. This review article is focused on the use of pyrazoles as suitable scaffolds for the development of 18F-labeled radiotracers for PET imaging. A brief introduction to PET and pyrazoles, as key scaffolds in medicinal chemistry, is presented, followed by a description of the most important [18F]pyrazole-derived radiotracers (PET tracers) that have been developed in the last 20 years for selective PET imaging, grouped according to their specific targets.
Collapse
|
3
|
Cybulska K, Perk L, Booij J, Laverman P, Rijpkema M. Huntington's Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers. Molecules 2020; 25:molecules25030482. [PMID: 31979301 PMCID: PMC7038198 DOI: 10.3390/molecules25030482] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Revised: 01/14/2020] [Accepted: 01/15/2020] [Indexed: 12/19/2022] Open
Abstract
Huntington’s disease (HD) is a fatal neurodegenerative disease caused by a CAG expansion mutation in the huntingtin gene. As a result, intranuclear inclusions of mutant huntingtin protein are formed, which damage striatal medium spiny neurons (MSNs). A review of Positron Emission Tomography (PET) studies relating to HD was performed, including clinical and preclinical data. PET is a powerful tool for visualisation of the HD pathology by non-invasive imaging of specific radiopharmaceuticals, which provide a detailed molecular snapshot of complex mechanistic pathways within the brain. Nowadays, radiochemists are equipped with an impressive arsenal of radioligands to accurately recognise particular receptors of interest. These include key biomarkers of HD: adenosine, cannabinoid, dopaminergic and glutamateric receptors, microglial activation, phosphodiesterase 10 A and synaptic vesicle proteins. This review aims to provide a radiochemical picture of the recent developments in the field of HD PET, with significant attention devoted to radiosynthetic routes towards the tracers relevant to this disease.
Collapse
Affiliation(s)
- Klaudia Cybulska
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 EZ Nijmegen, The Netherlands; (J.B.); (P.L.); (M.R.)
- Radboud Translational Medicine B.V., Radboud University Medical Center, Geert Grooteplein 21 (route 142), 6525 EZ Nijmegen, The Netherlands;
- Correspondence:
| | - Lars Perk
- Radboud Translational Medicine B.V., Radboud University Medical Center, Geert Grooteplein 21 (route 142), 6525 EZ Nijmegen, The Netherlands;
| | - Jan Booij
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 EZ Nijmegen, The Netherlands; (J.B.); (P.L.); (M.R.)
- Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
| | - Peter Laverman
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 EZ Nijmegen, The Netherlands; (J.B.); (P.L.); (M.R.)
| | - Mark Rijpkema
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein-Zuid 10, 6525 EZ Nijmegen, The Netherlands; (J.B.); (P.L.); (M.R.)
| |
Collapse
|
4
|
Mori W, Yamasaki T, Fujinaga M, Ogawa M, Zhang Y, Hatori A, Xie L, Kumata K, Wakizaka H, Kurihara Y, Ohkubo T, Nengaki N, Zhang MR. Development of 2-(2-(3-(4-([ 18F]Fluoromethoxy- d 2)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione for Positron-Emission-Tomography Imaging of Phosphodiesterase 10A in the Brain. J Med Chem 2018; 62:688-698. [PMID: 30516998 DOI: 10.1021/acs.jmedchem.8b01366] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Phosphodiesterase 10A (PDE10A) is a newly identified therapeutic target for central-nervous-system disorders. 2-(2-(3-(4-([18F]Fluoroethoxy)phenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione ([18F]MNI-659, [18F]5) is a useful positron-emission-tomography (PET) ligand for imaging of PDE10A in the human brain. However, the radiolabeled metabolite of [18F]5 can accumulate in the brain. In this study, using [18F]5 as a lead compound, we designed four new 18F-labeled ligands ([18F]6-9) to find one more suitable than [18F]5. Of these, 2-(2-(3-(4-([18F]fluoromethoxy- d2)phenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione ([18F]9) exhibited high in vitro binding affinity ( Ki = 2.9 nM) to PDE10A and suitable lipophilicity (log D = 2.2). In PET studies, the binding potential (BPND) of [18F]9 (5.8) to PDE10A in the striatum of rat brains was significantly higher than that of [18F]5 (4.6). Furthermore, metabolite analysis showed much lower levels of contamination with radiolabeled metabolites in the brains of rats given [18F]9 than in those given [18F]5. In conclusion, [18F]9 is a useful PET ligand for PDE10A imaging in brain.
Collapse
Affiliation(s)
| | | | | | - Masanao Ogawa
- SHI Accelerator Service, Ltd. , 1-17-6 Osaki , Shinagawa-ku, Tokyo 141-0032 , Japan
| | | | | | | | | | | | - Yusuke Kurihara
- SHI Accelerator Service, Ltd. , 1-17-6 Osaki , Shinagawa-ku, Tokyo 141-0032 , Japan
| | - Takayuki Ohkubo
- SHI Accelerator Service, Ltd. , 1-17-6 Osaki , Shinagawa-ku, Tokyo 141-0032 , Japan
| | - Nobuki Nengaki
- SHI Accelerator Service, Ltd. , 1-17-6 Osaki , Shinagawa-ku, Tokyo 141-0032 , Japan
| | | |
Collapse
|
5
|
Andrés JI, Schmidt M. Medicinal Chemistry strategies for PET tracer discovery. DRUG DISCOVERY TODAY. TECHNOLOGIES 2017; 25:11-17. [PMID: 29233262 DOI: 10.1016/j.ddtec.2017.10.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Revised: 09/29/2017] [Accepted: 10/10/2017] [Indexed: 06/07/2023]
Abstract
The detection of gamma rays, resulting from decay of positron emitting isotopes, allows exquisitely sensitive detection of probes radiolabeled with such isotopes. These probes can be designed for high affinity binding to specific molecular targets and be used as tools in the early development of drugs, particularly for neuropsychiatric disorders. Availability of novel tracers requires dedicated resources and selection assays. Many of the selection assays are similar to those used for discovery of clinical compounds, although the distribution and clearance of target specific radioligands requires different in vitro and in vivo methods and new derivatives.
Collapse
Affiliation(s)
- José Ignacio Andrés
- Discovery Sciences, Janssen Research & Development, Janssen-Cilag S. A., C/Jarama 75A, 45007 Toledo, Spain.
| | - Mark Schmidt
- Neuroscience Therapeutic Area, Janssen Research & Development, Division of Janssen Pharmaceutica, NV, Turnhoutseweg 30, Beerse 2340, Belgium
| |
Collapse
|
6
|
Mori W, Takei M, Furutsuka K, Fujinaga M, Kumata K, Muto M, Ohkubo T, Hashimoto H, Tamagnan G, Higuchi M, Kawamura K, Zhang MR. Comparison between [ 18F]fluorination and [ 18F]fluoroethylation reactions for the synthesis of the PDE10A PET radiotracer [ 18F]MNI-659. Nucl Med Biol 2017; 55:12-18. [PMID: 28972915 DOI: 10.1016/j.nucmedbio.2017.08.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Revised: 08/04/2017] [Accepted: 08/15/2017] [Indexed: 12/20/2022]
Abstract
INTRODUCTION 2-(2-(3-(4-(2-[18F]Fluoroethoxy)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione ([18F]MNI-659, [18F]1) is a useful PET radiotracer for imaging phosphodiesterase 10A (PDE10A) in human brain. [18F]1 has been previously prepared by direct [18F]fluorination of a tosylate precursor 2 with [18F]F-. The aim of this study was to determine the conditions for the [18F]fluorination reaction to obtain [18F]1 of high quality and with sufficient radioactivity for clinical use in our institute. Moreover, we synthesized [18F]1 by [18F]fluoroethylation of a phenol precursor 3 with [18F]fluoroethyl bromide ([18F]FEtBr), and the outcomes of [18F]fluorination and [18F]fluoroethylation were compared. METHODS We performed the automated synthesis of [18F]1 by [18F]fluorination and [18F]fluoroethylation using a multi-purpose synthesizer. We determined the amounts of tosylate precursor 2 and potassium carbonate as well as the reaction temperature for direct [18F]fluorination. RESULTS The efficiency of the [18F]fluorination reaction was strongly affected by the amount of 2 and potassium carbonate. Under the determined reaction conditions, [18F]1 with 0.82±0.2GBq was obtained in 13.6%±3.3% radiochemical yield (n=8, decay-corrected to EOB and based on [18F]F-) at EOS, starting from 11.5±0.4GBq of cyclotron-produced [18F]F-. On the other hand, the [18F]fluoroethylation of 3 with [18F]FEtBr produced [18F]1 with 1.0±0.2GBq and in 22.5±2.5 % radiochemical yields (n=7, decay-corrected to EOB and based on [18F]F-) at EOS, starting from 7.4GBq of cyclotron-produced [18F]F-. Clearly, [18F]fluoroethylation resulted in a higher radiochemical yield of [18F]1 than [18F]fluorination. CONCLUSION [18F]1 of high quality and with sufficient radioactivity was successfully radiosynthesized by two methods. [18F]1 synthesized by direct [18F]fluorination has been approved and will be provided for clinical use in our institute.
Collapse
Affiliation(s)
- Wakana Mori
- National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan
| | - Makoto Takei
- National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan
| | - Kenji Furutsuka
- National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; SHI Accelerator Service Ltd., Tokyo 141-0032, Japan
| | - Masayuki Fujinaga
- National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan
| | - Katsushi Kumata
- National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan
| | - Masatoshi Muto
- National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; Tokyo Nuclear Services Ltd., Tokyo 110-0016, Japan
| | - Takayuki Ohkubo
- National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan; SHI Accelerator Service Ltd., Tokyo 141-0032, Japan
| | - Hiroki Hashimoto
- National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan
| | | | - Makoto Higuchi
- National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan
| | - Kazunori Kawamura
- National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan
| | - Ming-Rong Zhang
- National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
| |
Collapse
|
7
|
Ahamed M, Attili B, van Veghel D, Ooms M, Berben P, Celen S, Koole M, Declercq L, Savinainen JR, Laitinen JT, Verbruggen A, Bormans G. Synthesis and preclinical evaluation of [ 11 C]MA-PB-1 for in vivo imaging of brain monoacylglycerol lipase (MAGL). Eur J Med Chem 2017; 136:104-113. [DOI: 10.1016/j.ejmech.2017.04.066] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Revised: 04/21/2017] [Accepted: 04/24/2017] [Indexed: 01/19/2023]
|
8
|
van der Born D, Pees A, Poot AJ, Orru RVA, Windhorst AD, Vugts DJ. Fluorine-18 labelled building blocks for PET tracer synthesis. Chem Soc Rev 2017; 46:4709-4773. [DOI: 10.1039/c6cs00492j] [Citation(s) in RCA: 113] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
This review presents a comprehensive overview of the synthesis and application of fluorine-18 labelled building blocks since 2010.
Collapse
Affiliation(s)
- Dion van der Born
- Department of Radiology & Nuclear Medicine
- VU University Medical Center
- 1081 HV Amsterdam
- The Netherlands
| | - Anna Pees
- Department of Radiology & Nuclear Medicine
- VU University Medical Center
- 1081 HV Amsterdam
- The Netherlands
| | - Alex J. Poot
- Department of Radiology & Nuclear Medicine
- VU University Medical Center
- 1081 HV Amsterdam
- The Netherlands
| | - Romano V. A. Orru
- Department of Chemistry and Pharmaceutical Sciences and Amsterdam Institute for Molecules
- Medicines & Systems (AIMMS)
- VU University Amsterdam
- Amsterdam
- The Netherlands
| | - Albert D. Windhorst
- Department of Radiology & Nuclear Medicine
- VU University Medical Center
- 1081 HV Amsterdam
- The Netherlands
| | - Danielle J. Vugts
- Department of Radiology & Nuclear Medicine
- VU University Medical Center
- 1081 HV Amsterdam
- The Netherlands
| |
Collapse
|
9
|
Wagner S, Teodoro R, Deuther-Conrad W, Kranz M, Scheunemann M, Fischer S, Wenzel B, Egerland U, Hoefgen N, Steinbach J, Brust P. Radiosynthesis and biological evaluation of the new PDE10A radioligand [ 18 F]AQ28A. J Labelled Comp Radiopharm 2016; 60:36-48. [PMID: 27896836 DOI: 10.1002/jlcr.3471] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Revised: 08/19/2016] [Accepted: 10/12/2016] [Indexed: 01/10/2023]
Abstract
Cyclic nucleotide phosphodiesterase 10A (PDE10A) regulates the level of the second messengers cAMP and cGMP in particular in brain regions assumed to be associated with neurodegenerative and psychiatric diseases. A better understanding of the pathophysiological role of the expression of PDE10A could be obtained by quantitative imaging of the enzyme by positron emission tomography (PET). Thus, in this study we developed, radiolabeled, and evaluated a new PDE10A radioligand, 8-bromo-1-(6-[18 F]fluoropyridin-3-yl)-3,4-dimethylimidazo[1,5-a]quinoxaline ([18 F]AQ28A). [18 F]AQ28A was radiolabeled by both nucleophilic bromo-to-fluoro or nitro-to-fluoro exchange using K[18 F]F-K2.2.2 -carbonate complex with different yields. Using the superior nitro precursor, we developed an automated synthesis on a Tracerlab FX F-N module and obtained [18 F]AQ28A with high radiochemical yields (33 ± 6%) and specific activities (96-145 GBq·μmol-1 ) for further evaluation. Initially, we investigated the binding of [18 F]AQ28A to the brain of different species by autoradiography and observed the highest density of binding sites in striatum, the brain region with the highest PDE10A expression. Subsequent dynamic PET studies in mice revealed a region-specific accumulation of [18 F]AQ28A in this region, which could be blocked by preinjection of the selective PDE10A ligand MP-10. In conclusion, the data suggest [18 F]AQ28A is a suitable candidate for imaging of PDE10A in rodent brain by PET.
Collapse
Affiliation(s)
- Sally Wagner
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Rodrigo Teodoro
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Winnie Deuther-Conrad
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Mathias Kranz
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Matthias Scheunemann
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Steffen Fischer
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Barbara Wenzel
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | | | | | - Jörg Steinbach
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| | - Peter Brust
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Research Site Leipzig, Department of Neuroradiopharmaceuticals, Leipzig, Germany
| |
Collapse
|
10
|
Ooms M, Attili B, Celen S, Koole M, Verbruggen A, Van Laere K, Bormans G. [18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP. J Neurochem 2016; 139:897-906. [DOI: 10.1111/jnc.13855] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Revised: 08/29/2016] [Accepted: 09/19/2016] [Indexed: 12/18/2022]
Affiliation(s)
- Maarten Ooms
- Laboratory for Radiopharmacy; Department of Pharmaceutical and Pharmacological Sciences KU Leuven; Leuven Belgium
| | - Bala Attili
- Laboratory for Radiopharmacy; Department of Pharmaceutical and Pharmacological Sciences KU Leuven; Leuven Belgium
| | - Sofie Celen
- Laboratory for Radiopharmacy; Department of Pharmaceutical and Pharmacological Sciences KU Leuven; Leuven Belgium
| | - Michel Koole
- Division of Nuclear Medicine; KU Leuven and University Hospital Leuven; Leuven Belgium
| | - Alfons Verbruggen
- Laboratory for Radiopharmacy; Department of Pharmaceutical and Pharmacological Sciences KU Leuven; Leuven Belgium
| | - Koen Van Laere
- Division of Nuclear Medicine; KU Leuven and University Hospital Leuven; Leuven Belgium
| | - Guy Bormans
- Laboratory for Radiopharmacy; Department of Pharmaceutical and Pharmacological Sciences KU Leuven; Leuven Belgium
| |
Collapse
|
11
|
Maftei E, Maftei CV, Jones PG, Freytag M, Franz MH, Kelter G, Fiebig HH, Tamm M, Neda I. Trifluoromethylpyridine-SubstitutedN-Heterocyclic Carbenes Related to Natural Products: Synthesis, Structure, and Potential Antitumor Activity of some Corresponding Gold(I), Rhodium(I), and Iridium(I) Complexes. Helv Chim Acta 2016. [DOI: 10.1002/hlca.201500529] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Elena Maftei
- Institut für Anorganische und Analytische Chemie; Technische Universität Carola Wilhelmina; Hagenring 30 DE-38106 Braunschweig
- Institutul National de Cercetare Dezvoltare pentru Electrochimie si Materie Condensata; Str. Dr. A. Paunescu Podeanu Nr. 144 RO-300569 Timisoara
| | - Catalin V. Maftei
- Institut für Anorganische und Analytische Chemie; Technische Universität Carola Wilhelmina; Hagenring 30 DE-38106 Braunschweig
- Institutul National de Cercetare Dezvoltare pentru Electrochimie si Materie Condensata; Str. Dr. A. Paunescu Podeanu Nr. 144 RO-300569 Timisoara
| | - Peter G. Jones
- Institut für Anorganische und Analytische Chemie; Technische Universität Carola Wilhelmina; Hagenring 30 DE-38106 Braunschweig
| | - Matthias Freytag
- Institut für Anorganische und Analytische Chemie; Technische Universität Carola Wilhelmina; Hagenring 30 DE-38106 Braunschweig
| | - M. Heiko Franz
- Institutul National de Cercetare Dezvoltare pentru Electrochimie si Materie Condensata; Str. Dr. A. Paunescu Podeanu Nr. 144 RO-300569 Timisoara
- InnoChemTech GmbH; Hagenring 30 DE-38106 Braunschweig
| | | | | | - Matthias Tamm
- Institut für Anorganische und Analytische Chemie; Technische Universität Carola Wilhelmina; Hagenring 30 DE-38106 Braunschweig
| | - Ion Neda
- Institut für Anorganische und Analytische Chemie; Technische Universität Carola Wilhelmina; Hagenring 30 DE-38106 Braunschweig
- Institutul National de Cercetare Dezvoltare pentru Electrochimie si Materie Condensata; Str. Dr. A. Paunescu Podeanu Nr. 144 RO-300569 Timisoara
| |
Collapse
|
12
|
Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012. Molecules 2016; 21:molecules21050650. [PMID: 27213312 PMCID: PMC6273803 DOI: 10.3390/molecules21050650] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Revised: 05/09/2016] [Accepted: 05/10/2016] [Indexed: 12/19/2022] Open
Abstract
Cyclic nucleotide phosphodiesterases (PDEs) are a class of intracellular enzymes that inactivate the secondary messenger molecules, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Thus, PDEs regulate the signaling cascades mediated by these cyclic nucleotides and affect fundamental intracellular processes. Pharmacological inhibition of PDE activity is a promising strategy for treatment of several diseases. However, the role of the different PDEs in related pathologies is not completely clarified yet. PDE-specific radioligands enable non-invasive visualization and quantification of these enzymes by positron emission tomography (PET) in vivo and provide an important translational tool for elucidation of the relationship between altered expression of PDEs and pathophysiological effects as well as (pre-)clinical evaluation of novel PDE inhibitors developed as therapeutics. Herein we present an overview of novel PDE radioligands for PET published since 2012.
Collapse
|
13
|
Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission. EJNMMI Radiopharm Chem 2016; 1:3. [PMID: 29564380 PMCID: PMC5843803 DOI: 10.1186/s41181-016-0005-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2015] [Accepted: 02/11/2016] [Indexed: 01/25/2023] Open
Abstract
Background Phosphodiesterase 10A (PDE10A) is an important regulator of
nigrostriatal dopamine (DA) neurotransmission. However, little is known on the
effect of alterations in DA neurotransmission on PDE10A availability. Here, we
used [18F]JNJ42259152 PET to measure changes in PDE10A
availability, secondary to pharmacological alterations in DA release and to
investigate whether these are D1- or
D2-receptor driven. Results Acute treatment of rats using D-amphetamine (5 mg, s.c. and 1 mg/kg
i.v.) did not result in a significant change in PDE10A BPND
compared to baseline conditions. 5-day D-amphetamine treatment (5 mg/kg, s.c.)
increased striatal PDE10A BPND compared to the baseline
(+24 %, p = 0.03). Treatment with the selective
D2 antagonist SCH23390 (1 mg/kg) and D-amphetamine decreased PDE10A binding
(-22 %, p = 0.03). Treatment with only SCH23390
further decreased PDE10A binding (-26 %, p = 0.03). No significant alterations in PDE10A mRNA levels were
observed. Conclusions Repeated D-amphetamine treatment significantly increased PDE10A
binding, which is not observed upon selective D1 receptor
blocking. This study suggests a potential pharmacological interaction between
PDE10A enzymes and drugs modifying DA neurotransmission. Therefore, PDE10A binding
in patients with neuropsychiatric disorders might be modulated by chronic
DA-related treatment. Electronic supplementary material The online version of this article (doi:10.1186/s41181-016-0005-5) contains supplementary material, which is available to authorized
users.
Collapse
|
14
|
Cox CD, Hostetler ED, Flores BA, Evelhoch JL, Fan H, Gantert L, Holahan M, Eng W, Joshi A, McGaughey G, Meng X, Purcell M, Raheem IT, Riffel K, Yan Y, Renger JJ, Smith SM, Coleman PJ. Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors. Bioorg Med Chem Lett 2015; 25:4893-4898. [PMID: 26077491 DOI: 10.1016/j.bmcl.2015.05.080] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2015] [Revised: 05/22/2015] [Accepted: 05/26/2015] [Indexed: 01/30/2023]
Abstract
Phosphodiesterase 10A (PDE10A) inhibition has recently been identified as a potential mechanism to treat multiple symptoms that manifest in schizophrenia. In order to facilitate preclinical development and support key proof-of-concept clinical trials of novel PDE10A inhibitors, it is critical to discover positron emission tomography (PET) tracers that enable plasma concentration/PDE10A occupancy relationships to be established across species with structurally diverse PDE10A inhibitors. In this Letter, we describe how a high-throughput screening hit was optimized to provide [(11)C]MK-8193 (8j), a PET tracer that supports the determination of plasma concentration/PDE10A occupancy relationships for structurally diverse series of PDE10A inhibitors in both rat and rhesus monkey.
Collapse
Affiliation(s)
- Christopher D Cox
- Discovery Chemistry, Merck Research Laboratories, West Point, PA 19486, USA.
| | | | - Broc A Flores
- Discovery Chemistry, Merck Research Laboratories, West Point, PA 19486, USA
| | | | - Hong Fan
- Imaging, Merck Research Laboratories, West Point, PA 19486, USA
| | - Liza Gantert
- Imaging, Merck Research Laboratories, West Point, PA 19486, USA
| | - Marie Holahan
- Imaging, Merck Research Laboratories, West Point, PA 19486, USA
| | - Waisi Eng
- Imaging, Merck Research Laboratories, West Point, PA 19486, USA
| | - Aniket Joshi
- Imaging, Merck Research Laboratories, West Point, PA 19486, USA
| | - Georgia McGaughey
- Chemical Modeling & Informatics, Merck Research Laboratories, West Point, PA 19486, USA
| | - Xiangjun Meng
- Imaging, Merck Research Laboratories, West Point, PA 19486, USA
| | - Mona Purcell
- Imaging, Merck Research Laboratories, West Point, PA 19486, USA
| | - Izzat T Raheem
- Discovery Chemistry, Merck Research Laboratories, West Point, PA 19486, USA
| | - Kerry Riffel
- Imaging, Merck Research Laboratories, West Point, PA 19486, USA
| | - Youwei Yan
- Structural Chemistry, Merck Research Laboratories, West Point, PA 19486, USA
| | - John J Renger
- Neuroscience, Merck Research Laboratories, West Point, PA 19486, USA
| | - Sean M Smith
- Neuroscience, Merck Research Laboratories, West Point, PA 19486, USA
| | - Paul J Coleman
- Discovery Chemistry, Merck Research Laboratories, West Point, PA 19486, USA
| |
Collapse
|
15
|
Phosphodiesterase 10A inhibitors: analysis of US/EP patents granted since 2012. Pharm Pat Anal 2015; 4:161-86. [DOI: 10.4155/ppa.15.11] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Phosphodiesterases are enzymes that metabolically inactivate the intracellular second messengers 3′,5′-cyclic adenosine and guanosine monophosphate contributing to the control of multiple biological processes. Among them, PDE10A has the most restricted distribution with high expression in striatal medium spiny neurons. Dysfunction of this key brain circuit has been associated with different psychiatric and neurodegenerative disorders. The unique role of PDE10A, together with its increased pharmacological characterization, have prompted enormous interest in investigating the potential of inhibitors of this enzyme as potential novel therapeutic agents This article reviews PDE10A related patents issued in the period 2012–2014 in the USA and Europe offering also a perspective on potential avenues for the future clinical development of phosphodiesterase 10A inhibitors.
Collapse
|
16
|
Hwang DR, Hu E, Allen JR, Davis C, Treanor J, Miller S, Chen H, Shi B, Narayanan TK, Barret O, Alagille D, Yu Z, Slifstein M. Radiosynthesis and initial characterization of a PDE10A specific PET tracer [18F]AMG 580 in non-human primates. Nucl Med Biol 2015; 42:654-63. [PMID: 25935386 DOI: 10.1016/j.nucmedbio.2015.04.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2014] [Revised: 03/12/2015] [Accepted: 04/10/2015] [Indexed: 01/02/2023]
Abstract
INTRODUCTION Phosphodiesterase 10A (PDE10A) is an intracellular enzyme responsible for the breakdown of cyclic nucleotides which are important second messengers for neurotransmission. Inhibition of PDE10A has been identified as a potential target for treatment of various neuropsychiatric disorders. To assist drug development, we have identified a selective PDE10A positron emission tomography (PET) tracer, AMG 580. We describe here the radiosynthesis of [(18)F]AMG 580 and in vitro and in vivo characterization results. METHODS The potency and selectivity were determined by in vitro assay using [(3)H]AMG 580 and baboon brain tissues. [(18)F]AMG 580 was prepared by a 1-step [(18)F]fluorination procedure. Dynamic brain PET scans were performed in non-human primates. Regions-of-interest were defined on individuals' MRIs and transferred to the co-registered PET images. Data were analyzed using two tissue compartment analysis (2TC), Logan graphical (Logan) analysis with metabolite-corrected input function and the simplified reference tissue model (SRTM) method. A PDE10A inhibitor and unlabeled AMG 580 were used to demonstrate the PDE10A specificity. KD was estimated by Scatchard analysis of high and low affinity PET scans. RESULTS AMG 580 has an in vitro KD of 71.9 pM. Autoradiography showed specific uptake in striatum. Mean activity of 121 ± 18 MBq was used in PET studies. In Rhesus, the baseline BPND for putamen and caudate was 3.38 and 2.34, respectively, via 2TC, and 3.16, 2.34 via Logan, and 2.92, and 2.01 via SRTM. A dose dependent decrease of BPND was observed by the pre-treatment with a PDE10A inhibitor. In baboons, 0.24 mg/kg dose of AMG 580 resulted in about 70% decrease of BPND. The in vivo KD of [(18)F]AMG 580 was estimated to be around 0.44 nM in baboons. CONCLUSION [(18)F]AMG 580 is a selective and potent PDE10A PET tracer with excellent specific striatal binding in non-human primates. It warrants further evaluation in humans.
Collapse
Affiliation(s)
- Dah-Ren Hwang
- Medical Sciences, 271 Running Water Ct, Ambler, PA 19002.
| | - Essa Hu
- Small Molecule Chemistry, Amgen Inc., Thousand Oaks, CA, USA
| | | | - Carl Davis
- Pharmacokinetics and Drug Metabolism, Amgen Inc., Thousand Oaks, CA, USA
| | | | - Silke Miller
- Neuroscience, Amgen Inc., Thousand Oaks, CA, USA
| | - Hang Chen
- Neuroscience, Amgen Inc., South San Francisco, USA
| | - Bingzhi Shi
- Department of Nuclear Medicine, Kettering Medical Center, Kettering, OH, USA
| | | | | | | | - Zhigang Yu
- Medical Sciences, 271 Running Water Ct, Ambler, PA 19002.
| | - Mark Slifstein
- Department of Psychiatry, Columbia University, New York, NY, USA; New York State Psychiatric Institute, NY, USA
| |
Collapse
|
17
|
Durham TB, Blanco MJ. Target Engagement in Lead Generation. Bioorg Med Chem Lett 2015; 25:998-1008. [DOI: 10.1016/j.bmcl.2014.12.076] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Revised: 12/15/2014] [Accepted: 12/23/2014] [Indexed: 12/15/2022]
|
18
|
Nenajdenko VG, Muzalevskiy VM, Shastin AV. Polyfluorinated ethanes as versatile fluorinated C2-building blocks for organic synthesis. Chem Rev 2015; 115:973-1050. [PMID: 25594605 DOI: 10.1021/cr500465n] [Citation(s) in RCA: 113] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Valentine G Nenajdenko
- Department of Chemistry, Moscow State University , Leninskie Gory, Moscow 119992, Russia
| | | | | |
Collapse
|
19
|
Bartolomé-Nebreda JM, Alonso de Diego SA, Artola M, Delgado F, Delgado Ó, Martín-Martín ML, Martínez-Viturro CM, Pena MÁ, Tong HM, Van Gool M, Alonso JM, Fontana A, Macdonald GJ, Megens A, Langlois X, Somers M, Vanhoof G, Conde-Ceide S. Identification of a Novel Orally Bioavailable Phosphodiesterase 10A (PDE10A) Inhibitor with Efficacy in Animal Models of Schizophrenia. J Med Chem 2015; 58:978-93. [DOI: 10.1021/jm501651a] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- José Manuel Bartolomé-Nebreda
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Sergio A. Alonso de Diego
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Marta Artola
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Francisca Delgado
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Óscar Delgado
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - María Luz Martín-Martín
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Carlos M. Martínez-Viturro
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Miguel Ángel Pena
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Han Min Tong
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Michiel Van Gool
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - José Manuel Alonso
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Alberto Fontana
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Gregor J. Macdonald
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Anton Megens
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Xavier Langlois
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Marijke Somers
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Greet Vanhoof
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Susana Conde-Ceide
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| |
Collapse
|
20
|
Chen H, Lester-Zeiner D, Shi J, Miller S, Glaus C, Hu E, Chen N, Able J, Biorn C, Wong J, Ma J, Michelsen K, Hill Della Puppa G, Kazules T, Dou HH, Talreja S, Zhao X, Chen A, Rumfelt S, Kunz RK, Ye H, Thiel OR, Williamson T, Davis C, Porter A, Immke D, Allen JR, Treanor J. AMG 580: a novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer. J Pharmacol Exp Ther 2014; 352:327-37. [PMID: 25502803 DOI: 10.1124/jpet.114.220517] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Phosphodiesterase 10A (PDE10A) inhibitors have therapeutic potential for the treatment of psychiatric and neurologic disorders, such as schizophrenia and Huntington's disease. One of the key requirements for successful central nervous system drug development is to demonstrate target coverage of therapeutic candidates in brain for lead optimization in the drug discovery phase and for assisting dose selection in clinical development. Therefore, we identified AMG 580 [1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)-2-fluoropropan-1-one], a novel, selective small-molecule antagonist with subnanomolar affinity for rat, primate, and human PDE10A. We showed that AMG 580 is suitable as a tracer for lead optimization to determine target coverage by novel PDE10A inhibitors using triple-stage quadrupole liquid chromatography-tandem mass spectrometry technology. [(3)H]AMG 580 bound with high affinity in a specific and saturable manner to both striatal homogenates and brain slices from rats, baboons, and human in vitro. Moreover, [(18)F]AMG 580 demonstrated prominent uptake by positron emission tomography in rats, suggesting that radiolabeled AMG 580 may be suitable for further development as a noninvasive radiotracer for target coverage measurements in clinical studies. These results indicate that AMG 580 is a potential imaging biomarker for mapping PDE10A distribution and ensuring target coverage by therapeutic PDE10A inhibitors in clinical studies.
Collapse
Affiliation(s)
- Hang Chen
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Dianna Lester-Zeiner
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Jianxia Shi
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Silke Miller
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Charlie Glaus
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Essa Hu
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Ning Chen
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Jessica Able
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Christopher Biorn
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Jamie Wong
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Ji Ma
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Klaus Michelsen
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Geraldine Hill Della Puppa
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Tim Kazules
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Hui Hannah Dou
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Santosh Talreja
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Xiaoning Zhao
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Ada Chen
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Shannon Rumfelt
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Roxanne K Kunz
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Hu Ye
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Oliver R Thiel
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Toni Williamson
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Carl Davis
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Amy Porter
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - David Immke
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - Jennifer R Allen
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| | - James Treanor
- Department of Neuroscience (H.C., D.L.-Z., J.A., C.B., H.H.D., S.T., A.P.), Department of Pharmacokinetics and Drug Metabolism (J.S., J.W., J.M.), and Department of Molecular Structures and Characterization (X.Z., A.C.), Amgen Inc., South San Francisco, California; Department of Neuroscience (S.M., G.H.D.P., D.I., J.T.), Department of Pharmacokinetics and Drug Metabolism (C.D.), Research Imaging Sciences (C.G., T.K., H.Y.), Department of Small Molecule Chemistry (E.H., N.C., S.R., R.K.K., J.R.A.), and Department of Process Development (O.R.T.), Amgen Inc., Thousand Oaks, California; and Department of Molecular Structures and Characterization (K.M.) and Department of Discovery Toxicology (T.W.), Amgen Inc., Cambridge, Massachusetts (K.M.)
| |
Collapse
|
21
|
Harada A, Suzuki K, Miura S, Hasui T, Kamiguchi N, Ishii T, Taniguchi T, Kuroita T, Takano A, Stepanov V, Halldin C, Kimura H. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A. Nucl Med Biol 2014; 42:146-54. [PMID: 25451212 DOI: 10.1016/j.nucmedbio.2014.09.005] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2014] [Revised: 09/02/2014] [Accepted: 09/04/2014] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Phosphodiesterase 10A (PDE10A) is a dual-substrate PDE that hydrolyzes both cAMP and cGMP and is selectively expressed in striatal medium spiny neurons. Recent studies have suggested that PDE10A inhibition is a novel approach for the treatment of disorders such as schizophrenia and Huntington's disease. A positron emission tomography (PET) occupancy study can provide useful information for the development of PDE10A inhibitors. We discovered T-773 as a candidate PET radioligand for PDE10A and investigated its properties by in vitro autoradiography and a PET study in a monkey. METHODS Profiling of T-773 as a PET radioligand for PDE10A was conducted by in vitro enzyme inhibitory assay, in vitro autoradiography, and PET study in a monkey. RESULTS T-773 showed a high binding affinity and selectivity for human recombinant PDE10A2 in vitro; the IC50 value in an enzyme inhibitory assay was 0.77nmol/L, and selectivity over other PDEs was more than 2500-fold. In autoradiography studies using mouse, rat, monkey, or human brain sections, radiolabeled T-773 selectively accumulated in the striatum. This selective accumulation was not observed in the brain sections of Pde10a-KO mice. The binding of [(3)H]T-773 to PDE10A in rat brain sections was competitively inhibited by MP-10, a selective PDE10A inhibitor. In rat brain sections, [(3)H]T-773 bound to a single high affinity site of PDE10A with Kd values of 12.2±2.2 and 4.7±1.2nmol/L in the caudate-putamen and nucleus accumbens, respectively. In a monkey PET study, [(11)C]T-773 showed good brain penetration and striatum-selective accumulation. CONCLUSION These results suggest that [(11)C]T-773 is a potential PET radioligand for PDE10A.
Collapse
Affiliation(s)
- Akina Harada
- CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Kazunori Suzuki
- CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Shotaro Miura
- CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Tomoaki Hasui
- CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Naomi Kamiguchi
- Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Tsuyoshi Ishii
- Biomolecular Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Takahiko Taniguchi
- CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Takanobu Kuroita
- CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan
| | - Akihiro Takano
- Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Vladimir Stepanov
- Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Christer Halldin
- Center for Psychiatric Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Haruhide Kimura
- CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
| |
Collapse
|
22
|
Piel M, Vernaleken I, Rösch F. Positron Emission Tomography in CNS Drug Discovery and Drug Monitoring. J Med Chem 2014; 57:9232-58. [DOI: 10.1021/jm5001858] [Citation(s) in RCA: 111] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Affiliation(s)
- Markus Piel
- Institute
of Nuclear Chemistry, Johannes Gutenberg-University, Fritz-Strassmann-Weg 2, D-55128 Mainz, Germany
| | - Ingo Vernaleken
- Department
of Psychiatry, Psychotherapy, and Psychosomatics, RWTH Aachen University, Pauwelsstraße 30, D-52074 Aachen, Germany
| | - Frank Rösch
- Institute
of Nuclear Chemistry, Johannes Gutenberg-University, Fritz-Strassmann-Weg 2, D-55128 Mainz, Germany
| |
Collapse
|
23
|
Kehler J, Kilburn JP, Estrada S, Christensen SR, Wall A, Thibblin A, Lubberink M, Bundgaard C, Brennum LT, Steiniger-Brach B, Christoffersen CT, Timmermann S, Kreilgaard M, Antoni G, Bang-Andersen B, Nielsen J. Discovery and development of 11C-Lu AE92686 as a radioligand for PET imaging of phosphodiesterase10A in the brain. J Nucl Med 2014; 55:1513-8. [PMID: 24994928 DOI: 10.2967/jnumed.114.140178] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
UNLABELLED Phosphodiesterase 10A (PDE10A) plays a key role in the regulation of brain striatal signaling, and several pharmaceutical companies currently investigate PDE10A inhibitors in clinical trials for various central nervous system diseases. A PDE10A PET ligand may provide evidence that a clinical drug candidate reaches and binds to the target. Here we describe the successful discovery and initial validation of the novel radiolabeled PDE10A ligand 5,8-dimethyl-2-[2-((1-(11)C-methyl)-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine ((11)C-Lu AE92686) and its tritiated analog (3)H-Lu AE92686. METHODS Initial in vitro experiments suggested Lu AE92686 as a promising radioligand, and the corresponding tritiated and (11)C-labeled compounds were synthesized. (3)H-Lu AE92686 was evaluated as a ligand for in vivo occupancy studies in mice and rats, and (11)C-Lu AE92686 was evaluated as a PET tracer candidate in cynomolgus monkeys and in humans. RESULTS (11)C-Lu AE92686 displayed high specificity and selectivity for PDE10A-expressing regions in the brain of cynomolgus monkeys and humans. Similar results were found in rodents using (3)H-Lu AE92686. The binding of (11)C-Lu AE92686 and (3)H-Lu AE92686 to striatum was completely and dose-dependently blocked by the structurally different PDE10A inhibitor 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (MP-10) in rodents and in monkeys. In all species, specific binding of the radioligand was seen in the striatum but not in the cerebellum, supporting the use of the cerebellum as a reference region. The binding potentials (BPND) of (11)C-Lu AE92686 in the striatum of both cynomolgus monkeys and humans were evaluated by the simplified reference tissue model with the cerebellum as the reference tissue, and BPND was found to be high and reproducible-that is, BPNDs were 6.5 ± 0.3 (n = 3) and 7.5 ± 1.0 (n = 12) in monkeys and humans, respectively. CONCLUSION Rodent, monkey, and human tests of labeled Lu AE92686 suggest that (11)C-Lu AE92686 has great potential as a human PET tracer for the PDE10A enzyme.
Collapse
Affiliation(s)
- Jan Kehler
- Division of Discovery Chemistry and DMPK, H. Lundbeck A/S, Valby, Denmark
| | - John Paul Kilburn
- Division of Discovery Chemistry and DMPK, H. Lundbeck A/S, Valby, Denmark
| | - Sergio Estrada
- Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
| | | | - Anders Wall
- Nuclear Medicine and PET, Uppsala University and Uppsala University Hospital, Uppsala, Sweden
| | - Alf Thibblin
- Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
| | - Mark Lubberink
- Nuclear Medicine and PET, Uppsala University and Uppsala University Hospital, Uppsala, Sweden
| | | | | | | | | | - Stine Timmermann
- Department of Quantitative Pharmacology, H. Lundbeck A/S, Valby, Denmark; and
| | - Mads Kreilgaard
- Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
| | - Gunnar Antoni
- Preclinical PET Platform, Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
| | - Benny Bang-Andersen
- Division of Discovery Chemistry and DMPK, H. Lundbeck A/S, Valby, Denmark Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
| | - Jacob Nielsen
- Division of Synaptic Transmission, H. Lundbeck A/S, Valby, Denmark
| |
Collapse
|
24
|
Ooms M, Rietjens R, Rangarajan JR, Vunckx K, Valdeolivas S, Maes F, Himmelreich U, Fernandez-Ruiz J, Bormans G, Van Laere K, Casteels C. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. Neurobiol Aging 2014; 35:2858-2869. [PMID: 25018107 DOI: 10.1016/j.neurobiolaging.2014.06.010] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2014] [Revised: 05/13/2014] [Accepted: 06/10/2014] [Indexed: 01/03/2023]
Abstract
Several lines of evidence imply early alterations in endocannabinoid and phosphodiesterase 10A (PDE10A) signaling in Huntington disease (HD). Using [(18)F]MK-9470 and [(18)F]JNJ42259152 small-animal positron emission tomography (PET), we investigated for the first time cerebral changes in type 1 cannabinoid (CB1) receptor binding and PDE10A levels in vivo in presymptomatic, early symptomatic, and late symptomatic HD (R6/2) mice, in relation to glucose metabolism ([(18)F]FDG PET), brain morphology (magnetic resonance imaging) and motor function. Ten R6/2 and 16 wild-type (WT) mice were investigated at 3 different time points between the age of 4 and 13 weeks. Parametric CB1 receptor and PDE10A images were anatomically standardized to Paxinos space and analyzed voxelwise. Volumetric microMRI imaging was performed to assess HD pathology. In R6/2 mice, CB1 receptor binding was decreased in comparison with WT in a cluster comprising the bilateral caudate-putamen, globus pallidus, and thalamic nucleus at week 5 (-8.1% ± 2.6%, p = 1.7 × 10(-5)). Longitudinal follow-up showed further progressive decline compared with controls in a cluster comprising the bilateral hippocampus, caudate-putamen, globus pallidus, superior colliculus, thalamic nucleus, and cerebellum (late vs. presymptomatic age: -13.7% ± 3.1% for R6/2 and +1.5% ± 4.0% for WT, p = 1.9 × 10(-5)). In R6/2 mice, PDE10A binding potential also decreased over time to reach significance at early and late symptomatic HD (late vs. presymptomatic age: -79.1% ± 1.9% for R6/2 and +2.1% ± 2.7% for WT, p = 1.5 × 10(-4)). The observed changes in CB1 receptor and PDE10A binding were correlated to anomalies exhibited by R6/2 animals in motor function, whereas no correlation was found with magnetic resonance imaging-based striatal volume. Our findings point to early regional dysfunctions in endocannabinoid and PDE10A signaling, involving the caudate-putamen and lateral globus pallidus, which may play a role in the progression of the disease in R6/2 animals. PET quantification of in vivo CB1 and/or PDE10A binding may thus be useful early biomarkers for HD. Our results also provide evidence of subtle motor deficits at earlier stages than previously described.
Collapse
Affiliation(s)
- Maarten Ooms
- Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; MoSAIC-Molecular Small Animal Imaging Centre, KU Leuven, Leuven, Belgium
| | - Roma Rietjens
- MoSAIC-Molecular Small Animal Imaging Centre, KU Leuven, Leuven, Belgium; Division of Nuclear Medicine, Department of Imaging and Pathology, KU Leuven and University Hospital Leuven, Leuven, Belgium
| | - Janaki Raman Rangarajan
- KU Leuven Medical Image Computing (ESAT/PSI), Department of Electrical Engineering & Medical Imaging Research Center, University Hospital Leuven, Leuven, Belgium
| | - Kathleen Vunckx
- Division of Nuclear Medicine, Department of Imaging and Pathology, KU Leuven and University Hospital Leuven, Leuven, Belgium
| | - Sara Valdeolivas
- Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
| | - Frederik Maes
- KU Leuven Medical Image Computing (ESAT/PSI), Department of Electrical Engineering & Medical Imaging Research Center, University Hospital Leuven, Leuven, Belgium
| | - Uwe Himmelreich
- Biomedical NMR Unit, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | - Javier Fernandez-Ruiz
- Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain; Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
| | - Guy Bormans
- Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; MoSAIC-Molecular Small Animal Imaging Centre, KU Leuven, Leuven, Belgium
| | - Koen Van Laere
- MoSAIC-Molecular Small Animal Imaging Centre, KU Leuven, Leuven, Belgium; Division of Nuclear Medicine, Department of Imaging and Pathology, KU Leuven and University Hospital Leuven, Leuven, Belgium
| | - Cindy Casteels
- MoSAIC-Molecular Small Animal Imaging Centre, KU Leuven, Leuven, Belgium; Division of Nuclear Medicine, Department of Imaging and Pathology, KU Leuven and University Hospital Leuven, Leuven, Belgium.
| |
Collapse
|
25
|
Ooms M, Celen S, Koole M, Langlois X, Schmidt M, De Angelis M, Andrés JI, Verbruggen A, Van Laere K, Bormans G. Synthesis and biological evaluation of carbon-11 and fluorine-18 labeled tracers for in vivo visualization of PDE10A. Nucl Med Biol 2014; 41:695-704. [PMID: 25002365 DOI: 10.1016/j.nucmedbio.2014.05.138] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2014] [Revised: 05/05/2014] [Accepted: 05/14/2014] [Indexed: 12/31/2022]
Abstract
INTRODUCTION In vivo visualization of PDE10A using PET provides a tool to evaluate the role of PDE10A in various neuropsychiatric diseases and can also be useful in the clinical evaluation of PDE10A inhibitor drug candidates. We evaluated several carbon-11 and fluorine-18 labeled PDE10A inhibitors as potential PDE10A PET radioligands. MATERIALS & METHODS [(11)C]MP10, [(11)C]JNJ42071965 and four other tracers were developed. Their biodistribution was evaluated in rats. Rat plasma and brain radiometabolites were quantified. Baseline microPET imaging was performed in normal rats and PDE10A knockout (KO) and wild-type (WT) mice. Blocking and displacement studies were conducted. The selectivity of the tracer binding was further studied in an ex vivo autoradiography experiment in PDE10A KO and WT mice. RESULTS Biodistribution showed brain uptake for all tracers in the striatum and wash-out from the cerebellum. [(11)C]1 ((11)C-MP10) had the highest specific uptake index (striatum (S) vs. cerebellum (C) ratios (S/C)-1) at 60 min (7.4). [(11)C]5 ([(11)C]JNJ42071965) had a high index at the early time points (1.0 and 3.7 at 2 and 30 min p.i., respectively). The affinity of [(11)C]4, [(18)F]3 and [(18)F]6 was too low to visualize PDE10A using microPET. [(11)C] 2 showed a specific binding, while kinetics of [(11)C]1 were too slow. [(11)C]5 reached equilibrium after 10 min (uptake index=1.2). Blocking and displacement experiments in rats and baseline imaging in PDE10A KO mice showed specific and reversible binding of [(11)C]5 to PDE10A. CONCLUSIONS We successfully radiolabeled and evaluated six radiotracers for their potential to visualize PDE10A in vivo. While [(11)C]1 had the highest striatal specific uptake index, its slow kinetics likely compromise clinical use of this tracer. [(11)C]5 has a relatively high striatum-to-background ratio and fast kinetic profile, which makes it a valuable carbon-11 alternative.
Collapse
Affiliation(s)
- Maarten Ooms
- Laboratory for Radiopharmacy, KU Leuven, Belgium; MoSAIC, Molecular Small Animal Imaging Centre, KU Leuven, Belgium
| | - Sofie Celen
- Laboratory for Radiopharmacy, KU Leuven, Belgium; MoSAIC, Molecular Small Animal Imaging Centre, KU Leuven, Belgium
| | - Michel Koole
- Department of Nuclear Medicine & Molecular Imaging, University Medical Center Groningen, The Netherlands
| | | | | | | | | | - Alfons Verbruggen
- Laboratory for Radiopharmacy, KU Leuven, Belgium; MoSAIC, Molecular Small Animal Imaging Centre, KU Leuven, Belgium
| | - Koen Van Laere
- MoSAIC, Molecular Small Animal Imaging Centre, KU Leuven, Belgium; Division of Nuclear Medicine, KU Leuven and University Hospital Leuven, Belgium
| | - Guy Bormans
- Laboratory for Radiopharmacy, KU Leuven, Belgium; MoSAIC, Molecular Small Animal Imaging Centre, KU Leuven, Belgium.
| |
Collapse
|
26
|
Plisson C, Weinzimmer D, Jakobsen S, Natesan S, Salinas C, Lin SF, Labaree D, Zheng MQ, Nabulsi N, Marques TR, Kapur S, Kawanishi E, Saijo T, Gunn RN, Carson RE, Rabiner EA. Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. J Nucl Med 2014; 55:595-601. [DOI: 10.2967/jnumed.113.131409] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
27
|
Hwang DR, Hu E, Rumfelt S, Easwaramoorthy B, Castrillon J, Davis C, Allen JR, Chen H, Treanor J, Abi-Dargham A, Slifstein M. Initial characterization of a PDE10A selective positron emission tomography tracer [11C]AMG 7980 in non-human primates. Nucl Med Biol 2014; 41:343-9. [PMID: 24607437 DOI: 10.1016/j.nucmedbio.2014.01.007] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2013] [Revised: 12/19/2013] [Accepted: 01/07/2014] [Indexed: 10/25/2022]
Abstract
INTRODUCTION Phosphodiesterase 10A (PDE10A) is an intracellular enzyme responsible for the breakdown of cyclic nucleotides which are important secondary messengers in the central nervous system. Inhibition of PDE10A has been identified as a potential therapeutic target for treatment of various neuropsychiatric disorders. To assist the drug development program, we have identified a selective PDE10A PET tracer, [(11)C]AMG 7980, for imaging PDE10A distribution using positron emission tomography. METHODS [(11)C]AMG 7980 was prepared in a one-pot, two-step reaction. Dynamic PET scans were performed in non-human primates following a bolus or bolus plus constant infusion tracer injection paradigm. Regions-of-interest were defined on individuals' MRIs and transferred to the co-registered PET images. Data were analyzed using Logan graphical analysis with metabolite-corrected input function, the simplified reference tissue model (SRTM) method and occupancy plots. A benchmark PDE10A inhibitor was used to demonstrate PDE10A-specific binding. RESULTS [(11)C]AMG 7980 was prepared with a mean specific activity of 99 ± 74 GBq/μmol (n=10) and a synthesis time of 45 min. Specific binding of the tracer was localized to the striatum and globus pallidus (GP) and low in other brain regions. Thalamus was used as the reference tissue to derive binding potentials (BPND). The BPND for caudate, putamen, and GP were 0.23, 0.65, 0.51, respectively by the graphical method, and 0.42, 0.76, and 0.75 from the SRTM method. A dose dependent decrease of BPND was observed with the pre-treatment of a PDE10A inhibitor. A bolus plus infusion injection paradigm yielded similar results. CONCLUSION [(11)C]AMG 7980 has been successfully used for imaging PDE10A in non-human primate brain. Despite the fast brain kinetics it can be used to measure target occupancy of PDE10A inhibitors in non-human primates and potentially applicable to humans.
Collapse
Affiliation(s)
- Dah-Ren Hwang
- Department of Medical Sciences, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1799, United States.
| | - Essa Hu
- Department of Small Molecule Chemistry, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Shannon Rumfelt
- Department of Small Molecule Chemistry, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Balu Easwaramoorthy
- Department of Psychiatry, Columbia University, New York, NY, USA; New York State Psychiatric Institute, NY, USA
| | | | - Carl Davis
- Department of Pharmacokinetics and Drug Metabolism, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Jennifer R Allen
- Department of Small Molecule Chemistry, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Hang Chen
- Department of Neuroscience, Amgen Inc., South San Francisco, CA
| | - James Treanor
- Department of Neuroscience, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, California 91320-1799, United States
| | - Anissa Abi-Dargham
- Department of Psychiatry, Columbia University, New York, NY, USA; Department of Radiology, Columbia University, New York, NY, USA; New York State Psychiatric Institute, NY, USA
| | - Mark Slifstein
- Department of Psychiatry, Columbia University, New York, NY, USA; New York State Psychiatric Institute, NY, USA
| |
Collapse
|
28
|
Van Laere K, Ahmad RU, Hudyana H, Dubois K, Schmidt ME, Celen S, Bormans G, Koole M. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain. J Nucl Med 2013; 54:1285-93. [PMID: 23843566 DOI: 10.2967/jnumed.112.118679] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
UNLABELLED Phosphodiesterase 10A (PDE10A) plays a central role in striatal signaling and is implicated in several neuropsychiatric disorders, such as movement disorders and schizophrenia. We performed initial brain kinetic modeling of the novel PDE10A tracer (18)F-JNJ-42259152 (2-[[4-[1-(2-(18)F-fluoroethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]-3,5-dimethyl-pyridine) and studied test-retest reproducibility in healthy volunteers. METHODS Twelve healthy volunteers (5 men, 7 women; age range, 42-77 y) were scanned dynamically up to 135 min after bolus injection of 172.5 ± 10.3 MBq of (18)F-JNJ42259152. Four volunteers (2 men, 2 women) underwent retest scanning, with a mean interscan interval of 37 d. Input functions and tracer parent fractions were determined using arterial sampling and high-performance liquid chromatography analysis. Volumes of interest for the putamen, caudate nucleus, ventral striatum, substantia nigra, thalamus, frontal cortex, and cerebellum were delineated using individual volumetric T1 MR imaging scans. One-tissue (1T) and 2-tissue (2T) models were evaluated to calculate total distribution volume (VT). Simplified models were also tested to calculate binding potential (BPND), including the simplified reference tissue model (SRTM) and multilinear reference tissue model, using the frontal cortex as the optimal reference tissue. The stability of VT and BPND was assessed down to a 60-min scan time. RESULTS The average intact tracer half-life in blood was 90 min. The 2T model VT values for the putamen, caudate nucleus, ventral striatum, substantia nigra, thalamus, frontal cortex, and cerebellum were 1.54 ± 0.37, 0.90 ± 0.24, 0.64 ± 0.18, 0.42 ± 0.09, 0.35 ± 0.09, 0.30 ± 0.07, and 0.36 ± 0.12, respectively. The 1T model provided significantly lower VT values, which were well correlated to the 2T VT. SRTM BPND values referenced to the frontal cortex were 3.45 ± 0.43, 1.78 ± 0.35, 1.10 ± 0.31, and 0.44 ± 0.09 for the respective target regions putamen, caudate nucleus, ventral striatum, and substantia nigra, with similar values for the multilinear reference tissue model. Good correlations were found for the target regions putamen, caudate nucleus, ventral striatum, and substantia nigra between the 2T-compartment model BPND and the SRTM BPND (r = 0.57, 0.82, 0.70, and 0.64, respectively). SRTM BPND using a 90- and 60-min acquisition interval showed low bias. Test-retest variability was 5%-19% for 2T VT and 5%-12% for BPND SRTM. CONCLUSION Kinetic modeling of (18)F-JNJ-42259152 shows that PDE10A activity can be reliably quantified and simplified using a reference tissue model with the frontal cortex as reference and a 60-min acquisition period.
Collapse
Affiliation(s)
- Koen Van Laere
- Department of Imaging and Pathology, Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Celen S, Koole M, Ooms M, De Angelis M, Sannen I, Cornelis J, Alcazar J, Schmidt M, Verbruggen A, Langlois X, Van Laere K, Andrés JI, Bormans G. Preclinical evaluation of [(18)F]JNJ42259152 as a PET tracer for PDE10A. Neuroimage 2013; 82:13-22. [PMID: 23664955 DOI: 10.1016/j.neuroimage.2013.04.123] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2012] [Revised: 04/24/2013] [Accepted: 04/27/2013] [Indexed: 01/26/2023] Open
Abstract
Phosphodiesterase-10A (PDE10A) is implicated in several neuropsychiatric disorders involving basal ganglia neurotransmission, such as schizophrenia, obsessive-compulsive disorder and Huntington's disease. To confirm target engagement and exposure-occupancy relationships of clinical candidates for treatment, and to further explore the in vivo biology of PDE10A, non-invasive imaging using a specific PET ligand is warranted. Recently we have reported the in vivo evaluation of [(18)F]JNJ41510417 which showed specific binding to PDE10A in rat striatum, but with relatively slow kinetics. A chemically related derivative JNJ42259152 was found to have a similar in vivo occupancy, but lower lipophilicity and lower PDE10A in vitro inhibitory activity compared to JNJ41510417. (18)F-labeled JNJ42259152 was therefore evaluated as a potential PDE10A PET radiotracer. Baseline PET in rats and monkey showed specific retention in the PDE10A-rich striatum, and fast wash-out, with a good contrast to non-specific binding, in other brain regions. Pretreatment and chase experiments in rats with the selective PDE10A inhibitor MP-10 showed that tracer binding was specific and reversible. Absence of specific binding in PDE10A knock-out (KO) mice further confirmed PDE10A specificity. In vivo radiometabolite analysis using high performance liquid chromatography (HPLC) showed presence of polar radiometabolites in rat plasma and brain. In vivo imaging in rat and monkey further showed faster brain kinetics, and higher striatum-to-cerebellum ratios for [(18)F]JNJ42259152 compared to [(18)F]JNJ41510417. The arterial input function corrected for radiometabolites was determined in rats and basic kinetic modeling was established. For a 60-min acquisition time interval, striatal binding potential of the intact tracer referenced to the cerebellum showed good correlation with corresponding binding potential values of a Simplified Reference Tissue Model and referenced Logan Plot, the latter using a population averaged reference tissue-to-plasma clearance rate and offering the possibility to generate representative parametric binding potential images. In conclusion we can state that in vivo imaging in PDE10A KO mice, rats and monkey demonstrates that [(18)F]JNJ42259152 provides a PDE10A-specific signal in the striatum with good pharmacokinetic properties. Although presence of a polar radiometabolite in rat brain yielded a systematic but reproducible underestimation of the striatal BPND, a Logan reference tissue model approach using 60 min acquisition data is appropriate for quantification.
Collapse
Affiliation(s)
- S Celen
- Laboratory for Radiopharmacy, KU Leuven, Leuven, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
|
31
|
Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging. Eur J Nucl Med Mol Imaging 2012; 40:254-61. [DOI: 10.1007/s00259-012-2270-1] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2012] [Accepted: 10/01/2012] [Indexed: 10/27/2022]
|
32
|
Andrés JI, Alcázar J, Cid JM, De Angelis M, Iturrino L, Langlois X, Lavreysen H, Trabanco AA, Celen S, Bormans G. Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging. J Med Chem 2012; 55:8685-99. [PMID: 22992024 DOI: 10.1021/jm300912k] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The synthesis and in vitro and in vivo evaluation of a new series of 7-(phenylpiperidinyl)-1,2,4-triazolo[4,3-a]pyridines, which were conveniently radiolabeled with carbon-11, as potential positron emission tomography (PET) radiotracers for in vivo imaging of the allosteric binding site of the metabotropic glutamate (mGlu) receptor subtype 2 are described. The synthesized compounds proved to be potent and selective positive allosteric modulators (PAMs) of the mGlu receptor 2 (mGluR2) in a [³⁵S]GTPγS binding assay and were able to displace an mGluR2 PAM radioligand, which we had previously developed, with IC₅₀ values in the low nanomolar range. The most promising candidates were radiolabeled and subjected to biodistribution studies and radiometabolite analysis in rats. Preliminary small-animal PET (μPET) studies in rats indicated that [¹¹C]20f binds specifically and reversibly to an mGluR2 allosteric site, strongly suggesting that it is a promising candidate for PET imaging of mGluR2 in the brain.
Collapse
Affiliation(s)
- José-Ignacio Andrés
- Medicinal Chemistry, Janssen Research & Development , Janssen-Cilag S.A., C/Jarama 75, 45007 Toledo, Spain.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Chappie TA, Helal CJ, Hou X. Current landscape of phosphodiesterase 10A (PDE10A) inhibition. J Med Chem 2012; 55:7299-331. [PMID: 22834877 DOI: 10.1021/jm3004976] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Thomas A Chappie
- Neuroscience Medicinal Chemistry, Pfizer, Inc. , 700 Main Street, Cambridge, MA 02139, USA.
| | | | | |
Collapse
|
34
|
Hu E, Ma J, Biorn C, Lester-Zeiner D, Cho R, Rumfelt S, Kunz RK, Nixey T, Michelsen K, Miller S, Shi J, Wong J, Hill Della Puppa G, Able J, Talreja S, Hwang DR, Hitchcock SA, Porter A, Immke D, Allen JR, Treanor J, Chen H. Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer. J Med Chem 2012; 55:4776-87. [PMID: 22548439 DOI: 10.1021/jm3002372] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A radiolabeled tracer for imaging therapeutic targets in the brain is a valuable tool for lead optimization in CNS drug discovery and for dose selection in clinical development. We report the rapid identification of a novel phosphodiesterase 10A (PDE10A) tracer candidate using a LC-MS/MS technology. This structurally distinct PDE10A tracer, AMG-7980 (5), has been shown to have good uptake in the striatum (1.2% ID/g tissue), high specificity (striatum/thalamus ratio of 10), and saturable binding in vivo. The PDE10A affinity (K(D)) and PDE10A target density (B(max)) were determined to be 0.94 nM and 2.3 pmol/mg protein, respectively, using [(3)H]5 on rat striatum homogenate. Autoradiography on rat brain sections indicated that the tracer signal was consistent with known PDE10A expression pattern. The specific binding of [(3)H]5 to rat brain was blocked by another structurally distinct, published PDE10A inhibitor, MP-10. Lastly, our tracer was used to measure in vivo PDE10A target occupancy of a PDE10A inhibitor in rats using LC-MS/MS technology.
Collapse
Affiliation(s)
- Essa Hu
- Department of Small Molecule Chemistry, Amgen Inc. , One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Radiosynthesis and Radiotracer Properties of a 7-(2-[18F]Fluoroethoxy)-6-methoxypyrrolidinylquinazoline for Imaging of Phosphodiesterase 10A with PET. Pharmaceuticals (Basel) 2012; 5:169-88. [PMID: 24288087 PMCID: PMC3763632 DOI: 10.3390/ph5020169] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2011] [Revised: 01/18/2012] [Accepted: 01/19/2012] [Indexed: 12/02/2022] Open
Abstract
Phosphodiesterase 10A (PDE10A) is a key enzyme of intracellular signal transduction which is involved in the regulation of neurotransmission. The molecular imaging of PDE10A by PET is expected to allow a better understanding of physiological and pathological processes related to PDE10A expression and function in the brain. The aim of this study was to develop a new 18F-labeled PDE10A ligand based on a 6,7-dimethoxy-4-pyrrolidinylquinazoline and to evaluate its properties in biodistribution studies. Nucleophilic substitution of the 7-tosyloxy-analogue led to the 7-[18F]fluoroethoxy-derivative [18F]IV with radiochemical yields of 25% ± 9% (n = 9), high radiochemical purity of ≥99% and specific activities of 110–1,100 GBq/μmol. [18F]IV showed moderate PDE10A affinity (KD,PDE10A = 14 nM) and high metabolic stability in the brain of female CD-1 mice, wherein the radioligand entered rapidly with a peak uptake of 2.3% ID/g in striatum at 5 min p.i. However, ex vivo autoradiographic and in vivo blocking studies revealed no target specific accumulation and demonstrated [18F]IV to be inapplicable for imaging PDE10A with PET.
Collapse
|
36
|
Recent Advances in the Development of PET and SPECT Tracers for Brain Imaging. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2012. [DOI: 10.1016/b978-0-12-396492-2.00008-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|